Insulin aspart (Huisheng Biological)

Primary objective: To compare the effectiveness of insulin aspart 30 injection and NovoRapid® 30 combined with metformin, in the treatment of patients with type 2 diabetes whose blood sugar is poorly controlled by oral hypoglycemic drugs (OADs); Secondary objective: To compare the safety of insulin aspart 30 injection and NovoRapid® 30 combined with metformin, in the treatment of patients with type 2 diabetes whose blood sugar is poorly controlled by oral hypoglycemic drugs (OADs).

The euglycemic clamp technique was used to compare the bioequivalence of the pharmacokinetics of single-dose subcutaneous injection of insulin aspart 30 injection developed by Jilin Jinsheng Pharmaceutical Co., Ltd. and NovoRapid® 30 (pen cartridge) in healthy male subjects;